ReviewNature reviews. Drug discovery2015
Prospects for the development of epigenetic drugs for CNS conditions.
Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 89 citations in OpenAlex.
- S-adenosylmethionine as an epigenetic treatment of depression in adults with childhood trauma.Epigenomics · 2026Trial
- Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in Schizophrenia.Current neuropharmacology · 2026Article
- Epigenetic regulation of targeted ferroptosis: A new strategy for drug development.Journal of pharmaceutical analysis · 2024Review
- Article
- Methylation Patterns of the FKBP5 Gene in Association with Childhood Maltreatment and Depressive Disorders.International journal of molecular sciences · 2024Article
- Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).Journal of medicinal chemistry · 2023Review
- SAMe, Choline, and Valproic Acid as Possible Epigenetic Drugs: Their Effects in Pregnancy with a Special Emphasis on Animal Studies.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Inhibitors of DNA Methylation.Advances in experimental medicine and biology · 2022Review
- SARS-CoV-2 (COVID-19) as a possible risk factor for neurodevelopmental disorders.Frontiers in neuroscience · 2022Review
- Advancement of epigenetics in stroke.Frontiers in neuroscience · 2022Review
- Associations of age, sex, sexual abuse, and genotype with monoamine oxidase a gene methylation.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Urine metabolic phenotyping in children with nocturnal enuresis and comorbid neurobehavioral disorders.Scientific reports · 2021Article
- The Role of Butyric Acid in Treatment Response in Drug-Naïve First Episode Schizophrenia.Frontiers in psychiatry · 2021Article
- Review
- Neurogenetic and Neuroepigenetic Mechanisms in Cognitive Health and Disease.Frontiers in molecular neuroscience · 2020Article
- The epigenetics of perinatal stress .Dialogues in clinical neuroscience · 2019Review
- Epigenetic therapy of Prader-Willi syndrome.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Hepcidin Mediates Transcriptional Changes in Ferroportin mRNA in Differentiated Neuronal-Like PC12 Cells Subjected to Iron Challenge.Molecular neurobiology · 2019Article
- FABP3 in the Anterior Cingulate Cortex Modulates the Methylation Status of the Glutamic Acid DecarboxylaseThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Association of Childhood Adversity With Differential Susceptibility of Transdiagnostic Psychopathology to Environmental Stress in Adulthood.JAMA network open · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Advances in our understanding of the epigenetic mechanisms that control gene expression in the central nervous system (CNS) and their role in neuropsychiatric disorders are paving the way for a potential new therapeutic approach that is focused on reversing the epigenetic underpinnings of neuropsychiatric conditions. In this article, the complexity of epigenetic processes and the current level of proof for their involvement in CNS disorders are discussed. The preclinical evidence for efficacy of pharmacological approaches that target epigenetics in the CNS and the particular challenges of this approach are also examined. Finally, strategies to address these challenges through the development of improved evidence-based epigenetic therapeutics and through combining pharmacological and behavioural approaches are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.